Breast Neoplasms Clinical Trials in Fort Worth, Texas

4 studies are recruiting for breast neoplasms in Fort Worth, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

    This is a Phase III trial where participants will be randomized to two treatment groups, which means participants will be assigned by equal chance to a treatment group. This trial will be double-blinded, which means neither the participants nor the trial doctors will know which of the two treatment…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    JPS Health Network - Trinity Springs Pavilion, Fort Worth, Texas
    Locations
    202 in total
    Run by
    BioNTech SE

    See if you can join NCT07173751 on ClinicalTrials.gov

  2. A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

    Researchers are looking for new ways to treat types of breast cancer that are both: * High-risk, which means the cancer may have a higher chance of getting worse or coming back after treatment * Early-stage, which means the cancer is in the breast or the lymph nodes around the breast The 2 types of…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    JPS Oncology and Infusion Center ( Site 0083), Fort Worth, Texas
    Locations
    325 in total
    Run by
    Merck Sharp & Dohme LLC

    See if you can join NCT06966700 on ClinicalTrials.gov

  3. A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

    The purpose of this study is to compare sacituzumab tirumotecan as a single agent, and in combination with pembrolizumab, versus Treatment of Physician's Choice (TPC) in participants with hormone receptor positive/human epidermal growth factor receptor-2 negative (HR+/HER2-) unresectable locally ad…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    The Center for Cancer and Blood Disorders ( Site 0041), Fort Worth, Texas
    Locations
    259 in total
    Run by
    Merck Sharp & Dohme LLC

    See if you can join NCT06312176 on ClinicalTrials.gov

  4. A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

    Researchers are looking for other ways to treat breast cancer (BC) that is hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) and either unresectable locally advanced or metastatic. * HR positive (HR+) means the cancer cells have proteins that attach to estr…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    JPS Health Network ( Site 0067), Fort Worth, Texas
    Locations
    199 in total
    Run by
    Merck Sharp & Dohme LLC

    See if you can join NCT07060807 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.